Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

A case of a patient with granulocyte-colony stimulating factor-producing pancreatic cancer who responded to nab-paclitaxel plus gemcitabine.

Kataoka K, Achiwa K, Minami Y, Fujita M, Naitoh T, Yamada M, Yamamoto H, Matsubara H, Urano F.

Nihon Shokakibyo Gakkai Zasshi. 2017;114(7):1277-1284. doi: 10.11405/nisshoshi.114.1277. Review. Japanese.

PMID:
28679984
2.

Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.

McBride A, Bonafede M, Cai Q, Princic N, Tran O, Pelletier C, Parisi M, Patel M.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1153-1160. doi: 10.1080/17512433.2017.1365598. Epub 2017 Aug 21.

PMID:
28795609
3.

Treatment of metastatic pancreatic adenocarcinoma: a review.

Thota R, Pauff JM, Berlin JD.

Oncology (Williston Park). 2014 Jan;28(1):70-4. Review.

4.

Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.

Kim GP, Parisi MF, Patel MB, Pelletier CL, Belk KW.

Expert Rev Clin Pharmacol. 2017 May;10(5):559-565. doi: 10.1080/17512433.2017.1302330. Epub 2017 Apr 19.

PMID:
28286977
5.

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M.

J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.

6.

Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.

Berger AK, Weber TF, Jäger D, Springfeld C.

Onkologie. 2013;36(12):763-5. doi: 10.1159/000356811. Epub 2013 Nov 20.

PMID:
24356569
7.

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

Portal A, Pernot S, Siauve N, Landi B, Lepère C, Colussi O, Rougier P, Zaanan A, Verrière B, Taieb J.

Clin Res Hepatol Gastroenterol. 2014 Apr;38(2):e23-6. doi: 10.1016/j.clinre.2014.01.005. Epub 2014 Feb 18.

PMID:
24559766
8.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.

Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group.

BMC Cancer. 2015 Oct 6;15:653. doi: 10.1186/s12885-015-1656-4.

9.

Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.

El Rassy E, Assi T, El Karak F, Ghosn M, Kattan J.

Clin Res Hepatol Gastroenterol. 2017 Mar;41(2):e26-e28. doi: 10.1016/j.clinre.2016.11.012. Epub 2017 Feb 17. No abstract available.

PMID:
28215539
10.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD.

J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb.

PMID:
25638248
11.

Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.

Le N, Vinci A, Schober M, Krug S, Javed MA, Kohlmann T, Sund M, Neesse A, Beyer G.

Digestion. 2016;94(4):222-229. doi: 10.1159/000453257. Epub 2016 Dec 29.

PMID:
28030863
12.

[Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].

Katsura Y, Takeda Y, Ohmura Y, Motoyama Y, Ishida T, Morimoto Y, Matsushita K, Naito A, Murakami K, Kagawa Y, Okishiro M, Takeno A, Egawa C, Kato T, Tamura S.

Gan To Kagaku Ryoho. 2015 Nov;42(12):2367-9. Japanese.

PMID:
26805366
13.

[A Case of Gemcitabine and Nab-Paclitaxel Therapy for Multiple Metastatic Pancreatic Cancer].

Takashima Y, Shibamoto J, Kawamura Y, Nishida M, Hiramoto H, Ochi F, Tsujiura M, Nakashima S, Fujiyama J, Masuyama M.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1826-1828. Japanese.

PMID:
29394789
14.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.

Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, Hammel P, Lecomte T, Dréanic J, Coriat R, Bachet JB, Dubreuil O, Marthey L, Dahan L, Tchoundjeu B, Locher C, Lepère C, Bonnetain F, Taieb J.

Br J Cancer. 2015 Sep 29;113(7):989-95. doi: 10.1038/bjc.2015.328. Epub 2015 Sep 15.

15.

Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case.

Kataoka K, Matsubara H, Urano F, Okamura S, Maeda M.

Nihon Shokakibyo Gakkai Zasshi. 2016;113(10):1777-1784. Japanese.

PMID:
27725467
16.

Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature.

Vinzens S, Zindel J, Zweifel M, Rau T, Gloor B, Wochner A.

Anticancer Res. 2017 Jan;37(1):223-228.

PMID:
28011495
17.

[A case of granulocyte-colony stimulating factor producing ductal adenocarcinoma of the pancreas].

Kawakami H, Kuwatani M, Fujiya Y, Uebayashi M, Konishi K, Makiyama H, Hashino S, Kubota K, Itoh T, Asaka M.

Nihon Shokakibyo Gakkai Zasshi. 2007 Feb;104(2):233-8. Japanese.

PMID:
17283419
18.

Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.

Ielpo B, Duran H, Diaz E, Fabra I, Caruso R, Ferri V, Malavé L, Hidalgo M, Alvarez R, Plaza C, Quijano Y, Vicente E.

Eur J Surg Oncol. 2016 Sep;42(9):1394-400. doi: 10.1016/j.ejso.2016.01.006. Epub 2016 Jan 29.

PMID:
26899943
19.

Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.

John P, Butler H, Saif MW.

Anticancer Res. 2014 Dec;34(12):7267-70.

PMID:
25503159
20.

Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.

Gharaibeh M, McBride A, Bootman JL, Patel H, Abraham I.

J Med Econ. 2017 Apr;20(4):345-352. doi: 10.1080/13696998.2016.1269015. Epub 2016 Dec 21.

PMID:
27919186

Supplemental Content

Support Center